Crossmark

Switching from complement inhibitors in AQP4-IgG–positive NMOSD: clinical characteristics, an operational “cluster phase” and potential strategies to prevent therapeutic gaps

Crossref DOI link: https://doi.org/10.1186/s12883-026-05130-x

Published Online: 2026-06-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sakurai, Kenzo https://orcid.org/0000-0002-9516-6753
Kaburagi, Kei

Isahaya, Kenji

Akiyama, Hisanao

Yamano, Yoshihisa
Funding

Funding for this research was provided by:

Practical Research Project for Rare/Intractable Diseases of the Japan Agency for Medical Research and Development

Rare and Intractable Diseases from the Ministry of Health, Labour and Welfare of Japan

Japan Society for the Promotion of Science (JSPS) KAKENHI
License Information

Text and Data Mining valid from 2026-06-29

Version of Record valid from 2026-09-16
More Information

Article History

Received: 18 March 2026

Accepted: 25 June 2026

First Online: 29 June 2026

Declarations

Ethics approval and consent to participate: This study was approved by the Institutional Review Board of St. Marianna University School of Medicine (Approval No. 6092). Written informed consent was obtained from all participants. This study was conducted in accordance with the Declaration of Helsinki.

Consent for publication: Written informed consent for publication was obtained from all patients.

Competing interests: The authors declare no competing interests.

Document is current

Any future updates will be listed below